Samsung Biologics, the Samsung Group’s contract biomanufacturing arm, reports third-quarter 2026 results showing net profit of 391.1 billion won ($295.2 million), down 21.2% year over year. The company says operating profit is 640.1 billion won, slightly higher than a year earlier at 633.5 billion won. Revenue increases 18.5% to 1.49 trillion won.

Outlets attribute the revenue growth to expanded production capacity, including full-scale operations at four plants in Songdo near Seoul and a ramp-up at a fifth plant. Samsung Biologics also points to contributions from its first U.S.-based biomanufacturing facility in Rockville, Maryland, acquired in March. Both sources say the firm is continuing to expand its contract development and manufacturing (CDMO) business, including by pursuing capacity and portfolio investments.

The company raises its 2026 annual sales growth guidance to 20%, up from an earlier range of 15% to 20%, citing progress in operations and business momentum. Reported cumulative contract orders for the year reach $22 billion, reinforcing the forward outlook mentioned in the filings.